184 related articles for article (PubMed ID: 31930187)
1. Dual-mechanistic antibody-drug conjugate
Nilchan N; Li X; Pedzisa L; Nanna AR; Roush WR; Rader C
Antib Ther; 2019 Oct; 2(4):71-78. PubMed ID: 31930187
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
3. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
[TBL] [Abstract][Full Text] [Related]
4. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
6. A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer.
Mckertish CM; Kayser V
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631234
[TBL] [Abstract][Full Text] [Related]
7. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
8. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C
Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903
[TBL] [Abstract][Full Text] [Related]
10. PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Graziani EI; Sung M; Ma D; Narayanan B; Marquette K; Puthenveetil S; Tumey LN; Bikker J; Casavant J; Bennett EM; Charati MB; Golas J; Hosselet C; Rohde CM; Hu G; Guffroy M; Falahatpisheh H; Finkelstein M; Clark T; Barletta F; Tchistiakova L; Lucas J; Rosfjord E; Loganzo F; O'Donnell CJ; Gerber HP; Sapra P
Mol Cancer Ther; 2020 Oct; 19(10):2068-2078. PubMed ID: 32747418
[TBL] [Abstract][Full Text] [Related]
11. Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation.
Hwang D; Nilchan N; Park H; Roy RN; Roush WR; Rader C
Bioconjug Chem; 2022 Jun; 33(6):1192-1200. PubMed ID: 35584359
[TBL] [Abstract][Full Text] [Related]
12. Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility.
Satomaa T; Pynnönen H; Vilkman A; Kotiranta T; Pitkänen V; Heiskanen A; Herpers B; Price LS; Helin J; Saarinen J
Antibodies (Basel); 2018 Mar; 7(2):. PubMed ID: 31544867
[TBL] [Abstract][Full Text] [Related]
13. A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies.
Osgood AO; Roy SJS; Koo D; Gu R; Chatterjee A
Bioconjug Chem; 2024 Apr; 35(4):457-464. PubMed ID: 38548654
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
15. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
[TBL] [Abstract][Full Text] [Related]
16. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
17. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
18. A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
Zhang L; Wang Z; Wang Z; Luo F; Guan M; Xu M; Li Y; Zhang Y; Wang Z; Wang W
Bioconjug Chem; 2021 Jun; 32(6):1094-1104. PubMed ID: 34013721
[TBL] [Abstract][Full Text] [Related]
19. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.
Zimmerman ES; Heibeck TH; Gill A; Li X; Murray CJ; Madlansacay MR; Tran C; Uter NT; Yin G; Rivers PJ; Yam AY; Wang WD; Steiner AR; Bajad SU; Penta K; Yang W; Hallam TJ; Thanos CD; Sato AK
Bioconjug Chem; 2014 Feb; 25(2):351-61. PubMed ID: 24437342
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
